Anti-MUC1 monoclonal antibody - OncoQuest

Drug Profile

Anti-MUC1 monoclonal antibody - OncoQuest

Alternative Names: Anti-MUC1 AR20.5; Anti-MUC1 mAb - Quest PharmaTech; AR20.5; BrevaRex; mAb-AR20.5

Latest Information Update: 19 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AltaRex
  • Developer OncoQuest; OncoVent; ViRexx Medical Corp
  • Class Monoclonal antibodies
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Preclinical Cancer
  • Discontinued Breast cancer; Multiple myeloma

Most Recent Events

  • 02 Nov 2016 Clinical trials in Pancreatic cancer in China (IV)
  • 02 Nov 2016 OncoVent plans a clinical trial for Pancreatic cancer in USA
  • 20 Oct 2016 Pharmacodynamics data from a preclinical trial in Pancreatic cancer released by OncoQuest
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top